In vitro kinetic assays for drug screening
Studies on a variety of animal models
Lead candidate selection and/or validation

Phase I/IIa

Target engagement
Dose optimization and scheduling
Single and multiple dosing

Phase II

Mild cognitive impairment/AD
PK/PD correlations
Responders versus non-responders

Phase III/IV

Adaptive drug trials
Drug responders
Clinical endpoint validation (PD correlations)